However, it is still a challenge to improve the anti-tumor efficacy of TCR-T immunotherapy, including how to expand the range of available TCRs in more patients, how to increase the safety and the functional avidity of therapeutic TCRs, and how to overcome the immunosuppressive effects of suppressor cell subsets in CD4+ T cells. The gene discussed is CD4; the disease is neoplasm.